MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Wednesday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is projected to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.97) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

MoonLake Immunotherapeutics Trading Up 3.3%

Shares of MLTX opened at $18.77 on Monday. The stock has a market capitalization of $1.21 billion, a P/E ratio of -5.65 and a beta of 1.20. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. The firm has a fifty day simple moving average of $15.24 and a two-hundred day simple moving average of $24.08.

Wall Street Analysts Forecast Growth

MLTX has been the subject of a number of analyst reports. The Goldman Sachs Group lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and increased their target price for the stock from $8.00 to $10.00 in a report on Wednesday, January 14th. Royal Bank Of Canada increased their price objective on MoonLake Immunotherapeutics from $10.00 to $12.00 and gave the stock a “sector perform” rating in a report on Friday. Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 29th. Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday, November 6th. Finally, UBS Group set a $24.00 price target on MoonLake Immunotherapeutics in a research note on Friday, January 9th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $25.92.

Insiders Place Their Bets

In related news, insider Kristian Reich sold 72,908 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $14.43, for a total transaction of $1,052,062.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Da Silva Jorge Santos sold 70,000 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the sale, the chief executive officer directly owned 2,878,577 shares in the company, valued at $41,710,580.73. The trade was a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 402,908 shares of company stock worth $5,987,162. Company insiders own 12.05% of the company’s stock.

Institutional Trading of MoonLake Immunotherapeutics

Hedge funds have recently made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter worth approximately $26,000. Bank of America Corp DE boosted its holdings in MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after acquiring an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after acquiring an additional 3,166 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of MoonLake Immunotherapeutics by 45.4% during the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after acquiring an additional 1,069 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in shares of MoonLake Immunotherapeutics during the fourth quarter valued at $47,000. 93.85% of the stock is owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.